Table 2.
Molecular and clinical characteristics of patients with primary myelofibrosis (PMF)
| Variables | CALR mutation (n = 19) | JAK2 mutation (n = 23) | Triple Negative (n = 3) | p-value |
|---|---|---|---|---|
| Males (%) | 13 (68.4) | 14 (60.9) | 1 (33.3) | 0.025* |
|
Age, Median (Range) |
45 (37–70) | 53 (21–76) | 43 (22–60) | 0.138 |
|
Haemoglobin (g/dL), Median (Range) |
10.5 (9.5–13.4) | 9.8 (6.6–15) | 7.9 (6.5–14.2) | 0.45 |
|
TLC ×109/L, Median (Range) |
9.8 (5.6–63.2) | 11.9 (1.8–22.1) | 40.9 (15.1–25) | 0.075 |
|
Platelet × 109/L, Median (Range) |
273 (122–1147) | 382.5 (12–239) | 131.5 (38–483) | 0.358 |
|
Circulating blasts (%), Median (Range) |
29 | 47.5 (44–51) | 38 | 0.306 |
| Reticulin Fibrosis | ||||
| MF 0 | 0 | 0 | 0 | |
| MF 1 | 5 (26.3) | 15 (65.2) | 2 (66.7) | 0.067 |
| MF 2 | 14 (73.7) | 8 (34.8) | 1 (33.3) | |
| Constitutional symptoms (%) | 12 (63.2) | 14 (60.9) | 3 (100) | 0.421 |
| DIPSS score, (%): | ||||
| Low | 4 (21.1) | 0 | 0 | |
| Intermediate-1 | 2 (10.5) | 5 (21.7) | 0 | 0.259 |
| Intermediate-2 | 9 (47.4) | 15 (65.2) | 3 (100) | |
| High | 4 (21.1) | 3 (13) | 0 | |
| Leukemic transformation, (%) | 2 (10.5) | 2 (8.7) | 1 (33.3) | 0.629 |
*significant